- Amid the high uncertainty in the equity markets, investors look at drawdown as a measure of a stock’s or a portfolio’s volatility.
- Starpharma Holdings shares have fared well driven by significant developments in its antiviral nasal spray as a potential COVID-19 treatment.
- Mesoblast shares have provided excellent returns led by favourable announcements concerning remestemcel-L for the treatment of ARDS due to COVID-19.
- Shares of Recce Pharmaceuticals have shot up driven by promising in-vitro study results for COVID-19 and Phase 1 trial initiation of RECCE® 327 synthetic antibiotics.
- Ongoing relaxation in rules and Canadian licence announcement have supported Althea’s share price growth.
- Telix Pharma has also weathered the storm with positive developments including Phase 1 trial initiation of APOMAB™, ODD for TLX102 for multiple myeloma, and BTD for TLX250-CDx, a renal cancer imaging product.
Amid the ongoing COVID-19 pandemic, the market has remained turbulent, showing the fluctuations in both directions. The uncertainty surrounding the pandemic has led to volatility in the stock markets.
Market participants, concerned about their investments, struggle to look for stocks that might help protect their portfolio from volatility, also measured by portfolio drawdown.
Despite several sectors and industries struggling during these tumultuous times, some ASX-listed healthcare stocks have outperformed during the existing scenario. These players achieved their set goals and generated significant returns.
Let us discuss five such ASX-listed healthcare companies - Starpharma, Mesoblast, Recce Pharmaceuticals, Althea, and Telix Pharmaceuticals.
Starpharma Holdings Limited (ASX:SPL)
On 22 September 2020, the share price of SPL stood at A$1.615 down by 2.417%. Shares of SPL generated an outstanding return of 145.19% in the last six months and 48.43% return in the previous three months (as on 21 September).
Melbourne-headquartered ASX 300 healthcare company Starpharma Holdings Limited is a global leader in the dendrimer products development for pharmaceutical, life science along with some other applications. VivaGel® portfolio and DEP® drug delivery are the two core developmental programs of Starpharma.
COVID-19 Nasal Spray SPL7013 Shows Virucidal Activity Against SARS-CoV-2
On 14 September 2020, Starpharma Holdings disclosed that the Company completed additional antiviral testing for SPL7013 nasal spray against novel coronavirus (SARS-CoV-2) at Scripps Research Institute in the United States. The latest findings confirm the potent virucidal activity of SPL7013.
The Company stated that at the concentration of nasal spray, SPL7013 inactivated over 99% of the coronavirus. Currently, Starpharma is swiftly advancing development including the regulatory and commercialisation for its antiviral nasal spray.
Moreover, SPL will expedite approval of SPL7013 and anticipates that product could be ready for the market during the 1H CY21.
Mesoblast Limited (ASX:MSB)
On 22 September 2020, MSB shares closed at A$5.020, up by 1.21%. MSB shares generated an exceptional return of 316.81% in the last six months and 34.05% in the previous three months (as on 21 September).
ASX 200 listed company Mesoblast Limited is a global leader in the development of off-the-shelf medicines. The Company operates in Singapore, the US, and Australia.
Mesoblast’s Remestemcel-L Nominated as Winner of 2020 Biotech Innovation Award
On 15 September 2020, regenerative medicine company Mesoblast revealed that its lead candidate remestemcel-L was nominated as the winner of the 2020 Fierce Innovation Awards for Biotech Innovation.
Remestemcel-L, that has recently been evaluated against COVID-19-induced acute respiratory distress syndrome (ARDS), received the major Fierce Biotech Innovation of the Year award.
Currently, Remestemcel-L is under priority evaluation by the US Food and Drug Administration for SR-aGVHD in children. The launch of remestemcel-L in the US is expected in 2020 if the FDA approves it.
Recce Pharmaceutical Ltd (ASX:RCE)
On 22 September 2020, the RCE shares ended at A$1.635, in line with the previous close. Shares of Recce Pharma generated an extraordinary return of 463.79% in the last six months and 127.08% in the previous three months (as on 21 September).
About Recce Pharmaceuticals
ASX-listed healthcare player Recce Pharmaceuticals Ltd is into the development & commercialisation of Synthetic Anti-Infectives (New Classes) designed for focusing the urgent health challenges of antibiotic-resistant superbugs and emerging viral pathogens across the world.
On 22 September 2020, Recce announced that its shares will remain paused until the earlier of 23 September 2020 or when the announcement is published.
Recce Pharmaceuticals enlisted CMAX Clinical Research to undertake a Phase 1 trial of RECCE® 327
On 10 September 2020, Recce Pharma disclosed that the Company had enlisted CMAX Clinical Research to undertake a Phase 1 clinical trial of RECCE® 327.
The Phase 1 clinical trial is to evaluate safety & tolerability of RECCE® 327 in healthy volunteers as a single ascending dose. The Company disclosed that first subjects are anticipated to be screened at the CMAX facility during the fourth quarter of 2020. CMAX facility is one of the largest, longest-running, and leading clinical trial facilities in Australia.
Althea Group Holdings Limited (ASX:AGH)
On 22 September 2020, the share price of Althea stood at A$0.550 down by 5.172%. Althea shares generated a return of 274.19% and 63.38% in the previous six and three months, respectively (As on 21 September).
About Althea Group-
ASX-listed global pharmaceutical company Althea Group Holdings Limited is a cannabis-based medicines producer and supplier. The Company also helps healthcare professionals and patients in navigating treatment pathways of medicinal cannabis.
Althea’s Canadian Subsidiary to Initiate Operations in Canada
On 14 September 2020, Althea announced a significant milestone related to the cannabis license grant to its Canadian subsidiary Peak Processing Solutions. The Company mentioned that Peak Processing Solutions would initiate commercial operations in Canada immediately.
Althea’s Canadian subsidiary shall manufacture Cannabis 2.0 products (cannabis-infused beverages, concentrates including topicals) on behalf of 3rd parties. Peak Processing Solutions will also supply medicinal products to pharmaceutical operations of Althea and significantly decreasing Althea’s cost of goods sold.
Peak Processing Solutions intends to generate almost C$25 million revenue in 18 months.
Telix Pharmaceutical Limited (ASX:TLX)
Telix Pharmaceutical’s shares last traded at A$1.750, down by 0.568% on 22 September 2020. Shares of Telix have generated returns of 120.00% and 39.13% in the last six and three months, respectively (As on 21 September).
About Telix Pharmaceuticals
Clinical-stage biopharmaceutical company Telix Pharmaceuticals Limited is engaged in the development of diagnostic and therapeutic products using the Molecularly Targeted Radiation. The Company develops a portfolio of clinical-stage oncology products to address unmet medical needs in brain, prostate, and kidney cancers.
First Patients Dosed in Novel Lung and Ovarian Cancer Theranostic
On 22 September 2020, Telix Pharma announced that in a Phase 1 trial of the novel ovarian and lung carcinoma theranostic APOMAB™ the first two patients have been dosed. The study is being done by the Central Adelaide Local Health Network and is co-funded by Telix & strategic partner, AusHealth®. The Company disclosed that the trial would enrol a total of 18 patients.
The study is aimed to evaluate how well APOMAB is capable of potentially delivering diagnostic and therapeutic targeted radiation for advancing ovarian and lung carcinomas. Telix stated that APOMAB has the potential to be used for numerous cancer indications.
There is no one left untouched by the charm of the multibillion-dollar global boom in cannabis. Its glorious journey from a criminalized drug to being used in over 20 countries for treating medical conditions.
No wonder the cannabis stocks are on the edge of a green rush. Don’t miss out on the happenings in the cannabis sector and take advantage of the growth phase of this sector by subscribing to our report on Marijuana stocks in Australia.
Find out the drivers for the rise in cannabis stock rates Even though the cannabis sector is in its growing phase, Australian cannabis stocks have already started to rise actively due to a hastily increasing patient base, and a legislative landscape that is gradually beginning to liberalise.
Outreach and future of cannabis stocks As countries liberalise regulation for medical and recreational use of cannabis, it is predicted that the industry would grow sharply in upcoming years The global cannabis market stands currently at around $8 billion and it is expected that the hemp derived CBD market to hit approximately $22 billion by 2022.
Key Players in the sector Althea Group Holdings Limited (ASX: AGH) and Cann Group Limited (ASX: CAN) are amongst the top players. Other Australia cannabis market players are- MGC Pharmaceuticals Ltd (ASX: MXC), Elixinol Global Limited (ASX: EXL), THC Global Group Limited (ASX: THC), AusCann Group Holdings Limited (ASX: AC8)